These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 199852)

  • 1. Regulation of nigro-striatal dopaminergic neurotransmission in the rat.
    Dray A; Fowler LJ; Oakley NR; Simmonds MA; Tanner T
    Neuropharmacology; 1977; 16(7-8):511-8. PubMed ID: 199852
    [No Abstract]   [Full Text] [Related]  

  • 2. [Stereotyped behavior and the nigro-strio-nigral system].
    Arushanian EB
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1985; 35(5):819-32. PubMed ID: 2866641
    [No Abstract]   [Full Text] [Related]  

  • 3. Substantia nigra as a station that not only transmits, but also transforms, incoming signals for its behavioural expression: striatal dopamine and GABA-mediated responses of pars reticulata neurons.
    Cools AR; Jaspers R; Kolasiewicz W; Sontag KH; Wolfarth S
    Behav Brain Res; 1983 Jan; 7(1):39-49. PubMed ID: 6297521
    [No Abstract]   [Full Text] [Related]  

  • 4. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.
    Hefti F; Melamed E; Sahakian BJ; Wurtman RJ
    Pharmacol Biochem Behav; 1980 Feb; 12(2):185-8. PubMed ID: 7189592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The striatonigral fibres and the feedback control of dopamine metabolism.
    Tulloch IF; Arbuthnott GW; Wright AK; Garcia-Munoz M; Nicolaou NM
    Psychol Med; 1978 Aug; 8(3):471-82. PubMed ID: 30106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic--GABA-ergic interaction in the nigrostriatal system.
    Koltai MZ; György L
    Acta Physiol Acad Sci Hung; 1981; 58(3):225-33. PubMed ID: 7348023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological evidence about nigro-striatal inhibition related to intrinsic GABA in the caudate nucleus deprived of dopaminergic synaptic activity.
    Feltz P
    Appl Neurophysiol; 1979; 42(1-2):47-50. PubMed ID: 222207
    [No Abstract]   [Full Text] [Related]  

  • 8. Substantia nigra as an out-put station for striatal dopaminergic responses: role of a GABA-mediated inhibition of pars reticulata neurons.
    Di Chiara G; Porceddu ML; Morelli M; Mulas ML; Gessa GL
    Naunyn Schmiedebergs Arch Pharmacol; 1979 Mar; 306(2):153-9. PubMed ID: 571967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 10. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 11. Rotational behaviour and striatal dopamine metabolism following unilateral activation of nigral GABA mechanisms: GABA-like modulation of dopaminergic and non-dopaminergic neurons in rat substantia nigra [proceedings].
    Waddington JL
    Br J Pharmacol; 1978 Jun; 63(2):384P. PubMed ID: 566600
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of d-amphetamine on dopaminergic neurotransmission; a comparison between the substantia nigra and the striatum.
    Elverfors A; Nissbrandt H
    Neuropharmacology; 1992 Jul; 31(7):661-70. PubMed ID: 1328918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neurophysiologic and pharmacologic evidence of autoregulationin the nigrostriatal system].
    Arushanian EB; Tolpyshev BA
    Biull Eksp Biol Med; 1981 Feb; 91(2):133-6. PubMed ID: 7194700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 15. Apomorphine and amphetamine stereotypy after 6-hydroxydopamine lesions of the substantia nigra.
    Price MT; Fibiger HC
    Eur J Pharmacol; 1974 Dec; 29(2):249-52. PubMed ID: 4613562
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibitory mechanisms in the substantia nigra and the dopamine pathway.
    Straughan DW; James TA
    Int J Neurol; 1979; 13(1-4):81-93. PubMed ID: 122391
    [No Abstract]   [Full Text] [Related]  

  • 17. Two kinds of nigrostriatal asymmetry: relationship to dopaminergic drug sensitivity and 6-hydroxydopamine lesion effects in Long-Evans rats.
    Glick SD; Hinds PA; Baird JL
    Brain Res; 1988 May; 450(1-2):334-41. PubMed ID: 3135915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotational behavior induced by unilateral electrical stimulations of nigro-striatal dopamine neurons: modification by low doses of apomorphine.
    Barghon R; Costentin JH
    Eur J Pharmacol; 1980 May; 64(1):39-46. PubMed ID: 6969658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of dopamine metabolism in solid fetal substantia nigra transplants and their terminals in the host striatum.
    Meloni R; Gale K
    Prog Brain Res; 1990; 82():467-71. PubMed ID: 2127112
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions.
    Slater P; Crossman AR
    Neuropharmacology; 1980 Mar; 19(3):289-95. PubMed ID: 7191487
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.